Nuburu, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nuburu, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $152.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.09M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.44M | Nov 8, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $152.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.09M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.44M | Nov 8, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($181.4K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.61M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($3.42M) | Nov 8, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($34.52M) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | ($4.35M) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | ($12.64M) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | ($5.71M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($20.71M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($29.52M) | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | $17.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.90M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.38M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($13.15M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($21.73M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($14.00M) | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | ($5.57M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($387.4K) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $174.6K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.82M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.46M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $4.55M | Nov 8, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.62M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($17.54M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($10.23M) | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | ($1.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($454.9K) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.71M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.17M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $536.0K | Nov 8, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.82M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.57M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.12M | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | $335.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $336.84M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.00M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.92M | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | $20.19M | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | $19.30M | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | $21.52M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $19.22M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $30.35M | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | $29.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $49.01M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.18M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($37.84M) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | ($36.31M) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | ($34.79M) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | ($37.43M) | Apr 15, 2025 |
| FY2025 | Dec 31, 2023 | ($32.55M) | Mar 31, 2026 |
| FY2023 | Sep 30, 2023 | ($34.89M) | Nov 8, 2024 |
| FY2023 | Jun 30, 2023 | ($30.41M) | Nov 8, 2024 |
| FY2023 | Mar 31, 2023 | ($29.55M) | Nov 8, 2024 |
| FY2024 | Dec 31, 2022 | ($17.23M) | Apr 15, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($200.48M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($131.81M) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | ($120.02M) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | ($115.63M) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | ($102.99M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($97.29M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($92.54M) | Nov 8, 2024 |
| FY2023 | Jun 30, 2023 | ($87.45M) | Nov 8, 2024 |
| FY2023 | Mar 31, 2023 | ($81.35M) | Nov 8, 2024 |
| FY2023 | Dec 31, 2022 | ($76.58M) | Nov 8, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $209.3K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.15M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.88M | Nov 8, 2024 |
| FY2022 | Dec 31, 2021 | $479.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.25M | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.46M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $9.24M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $9.12M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $22.69M | Nov 8, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (29) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | (1) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | (7) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Nov 8, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (29) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | (1) | Apr 15, 2025 |
| FY2024 | Jun 30, 2024 | (7) | Apr 15, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Nov 8, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.82M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 4.06M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 922,362 | Apr 15, 2025 |
| FY2024 | Jan 31, 2023 | 783,098 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 5.56M | Nov 8, 2024 |